Drug Trial Radar · NCT07550816
Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
May 27, 2026
Primary completion
Dec 5, 2026
Study completion Mar 26, 2027
Sponsor
- Lead sponsor
- Beijing QL Biopharmaceutical Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
ZT002 is an ultralong-acting glucagon-like peptide-1. This open-label, fixed sequence, two-period crossover drug-drug interaction study is designed to evaluate the impact of ZT002 on the PK of metformin, warfarin, rosuvastatin and digoxin. The study will include obese and overweight but otherwise healthy participants aged 18 - 45. The study consists of two cohorts. Each participant can only join one of the cohorts. Cohort 1 evaluates the impact of ZT002 on the PK of metformin at steady state and on the PK of a single dose of warfarin. Participants are screened within 2 weeks before study drug administration. In the first period, metformin is given twice daily for 3.5 days and warfarin is given as a single dose without ZT002. In the second period, metformin and warfarin are given, following the same dose and regimen as in the first period, concomitantly with ZT002, which reaches steady state by up-titration. The participants will be followed up for 6 weeks after the last dose of ZT002. Cohort 2 evaluates the impact of ZT002 on the PK of single doses of rosuvastatin and digoxin. Participants are screened within 2 weeks before study drug administration. In the first period, rosuvastatin and digoxin are given as single doses without ZT002. In the second period, rosuvastatin and digoxin are given, following the same dose and regimen as in the first period, concomitantly with ZT002, which reaches steady state by up-titration. The participants will be followed up for 6 weeks after the last dose of ZT002.
Conditions
- Overweight,Obesity
Interventions
ZT002 injection, metformin, warfarinDrug
Drug: metformin Participants will receive metformin twice daily for 3.5 days in both periods Drug: warfarin Participants will receive a single dose of warfarin in both periods Drug: ZT002 Participants will receive multiple doses of ZT002 in the second period
ZT002 injection, rosuvastatin, digoxinDrug
Drug: rosuvastatin Participants will receive a single dose of rosuvastatin in both periods Drug: digoxin Participants will receive a single dose of digoxin in both periods Drug: ZT002 Participants will receive multiple doses of ZT002 in the second period
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time curve of metformin within dosing interval (12 hours) at steady stateTime frame: From Day 4 to Day 5, from Day 112 to Day 113
- Area under the concentration-time curve of S-warfarin from time zero to infinity after single-dose administrationTime frame: From Day 6 to Day 13, from Day 126 to Day 133
- Area under the concentration-time curve of R-warfarin from time zero to infinity after single-dose administrationTime frame: From Day 6 to Day 13, from Day 126 to Day 133
- Area under the concentration-time curve of rosuvastatin from time zero to infinity after single-dose administrationTime frame: From Day 1 to Day 5, from Day 111 to Day 115
- Area under the concentration-time curve of digoxin from time zero to infinity after single-dose administrationTime frame: From Day 5 to Day 12, from Day 125 to Day 132
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Second Hospital, Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.